Scholarlink

<p><i>Cinnamomum migao</i> fructus (CO), a plant used in traditional medicine and cuisine, has demonstrated potential in treating coronary heart disease (CHD). However, its active compounds and mechanisms of action remain unclear. This study employed an integrated approach using gas chromatography–mass spectrometry (GC–MS), pharmacodynamic evaluation in a CHD mouse model, network pharmacology, and transcriptomics to systematically investigate the active constituents and therapeutic mechanisms of CO-pressed oil (CO-PO). GC–MS analysis identified 35 volatile compounds in CO-PO, predominantly terpenoids, with consistent chemical profiles across replicates. Key bioactive compounds included eucalyptol (6.63–26.86%). Pharmacological experiments demonstrated that CO-PO provided dose-dependent cardioprotection, significantly reducing serum levels of inflammatory markers and alleviating oxidative stress. CO-PO treatment also downregulated the expression of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Inducible Nitric Oxide Synthase (iNOS) in myocardial tissue (<i>P</i> &lt; 0.05). Network pharmacology identified seven bioactive compounds, including decanoic acid and <i>γ</i>-eudesmol, which target 109 CHD-related genes. Transcriptomic analysis revealed 25 differentially expressed genes that were reversed by CO-PO treatment, such as Interferon-induced transmembrane protein 3 (Ifitm3) and Cathepsin S (Ctss). Pathway enrichment analysis highlighted several key pathways, including those related to Coronavirus Disease (COVID-19), ribosome function, and efferocytosis. These findings indicate that CO-PO ameliorates CHD through a complex "multi-component, multi-target, multi-pathway" network, supporting its potential development as a functional food ingredient.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrated multi-omics analysis of Cinnamomum migao fructus pressed oil for coronary heart disease

  • 期刊论文

  • 发表日期：

    2026年1月22日

查看全文
  • Yi Luo,
  • Jiang-Tao Guo,
  • Yong-Ping Zhang,
  • Li-Na Jian,
  • Jian Xu,
  • Jie Liu

摘要

Cinnamomum migao fructus (CO), a plant used in traditional medicine and cuisine, has demonstrated potential in treating coronary heart disease (CHD). However, its active compounds and mechanisms of action remain unclear. This study employed an integrated approach using gas chromatography–mass spectrometry (GC–MS), pharmacodynamic evaluation in a CHD mouse model, network pharmacology, and transcriptomics to systematically investigate the active constituents and therapeutic mechanisms of CO-pressed oil (CO-PO). GC–MS analysis identified 35 volatile compounds in CO-PO, predominantly terpenoids, with consistent chemical profiles across replicates. Key bioactive compounds included eucalyptol (6.63–26.86%). Pharmacological experiments demonstrated that CO-PO provided dose-dependent cardioprotection, significantly reducing serum levels of inflammatory markers and alleviating oxidative stress. CO-PO treatment also downregulated the expression of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Inducible Nitric Oxide Synthase (iNOS) in myocardial tissue (P < 0.05). Network pharmacology identified seven bioactive compounds, including decanoic acid and γ-eudesmol, which target 109 CHD-related genes. Transcriptomic analysis revealed 25 differentially expressed genes that were reversed by CO-PO treatment, such as Interferon-induced transmembrane protein 3 (Ifitm3) and Cathepsin S (Ctss). Pathway enrichment analysis highlighted several key pathways, including those related to Coronavirus Disease (COVID-19), ribosome function, and efferocytosis. These findings indicate that CO-PO ameliorates CHD through a complex "multi-component, multi-target, multi-pathway" network, supporting its potential development as a functional food ingredient.